This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Monster Beverage's Strategies Cushion the Stock in 2019?
by Zacks Equity Research
Monster Beverage (MNST) witnesses strained margins, owing to higher expenses. However, its solid energy drink category and other efforts are encouraging.
Molson Coors (TAP) Shows Resilience: Stock to Surge in 2019?
by Zacks Equity Research
Molson Coors (TAP) displays momentum backed by focus on cost savings and premiumization of its portfolio, which has boosted its top and bottom lines.
Here's Why You Should Hold on to Keurig Dr Pepper Stock Now
by Zacks Equity Research
Keurig Dr Pepper's (KDP) strong performance in third-quarter 2018 and a promising outlook, alongside its partnerships and acquisition strategy, position it for growth in the future.
Why Is Keurig Dr Pepper (KDP) Down 8.8% Since Last Earnings Report?
by Zacks Equity Research
Keurig Dr Pepper (KDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Twitter, Lockheed Martin, Intercontinental Exchange, CBRE and Keurig Dr Pepper
by Zacks Equity Research
Zacks.com featured highlights include: Twitter, Lockheed Martin, Intercontinental Exchange, CBRE and Keurig Dr Pepper
The Zacks Analyst Blog Highlights: PetroChina, NextEra, Eni, Dr Pepper and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PetroChina, NextEra, Eni, Dr Pepper and Regeneron
Buy These 5 Stocks With Sales Growth Amid Volatile Markets
by Zacks Equity Research
A company can improve earnings by controlling costs and maintaining stable revenues. But superior profits can only be generated through steady sales growth.
Top Stock Reports for PetroChina, NextEra & Eni
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PetroChina (PTR), NextEra (NEE) and Eni (E).
Time to Buy Coca-Cola (KO) Stock Near New All-Time High?
by Benjamin Rains
Should investors consider buying Coca-Cola stock with its shares up 11% over the last month alone?
Keurig Dr Pepper (KDP) Beats on Q3 Earnings, Retains View
by Zacks Equity Research
Keurig Dr Pepper's (KDP) reports third-quarter 2018 results, wherein earnings beat estimates and sales lag. The company remains optimistic about its long-term growth targets.
Can Keurig Dr Pepper (KDP) Deliver Earnings Beat in Q3?
by Zacks Equity Research
Keurig Dr Pepper (KDP) is poised to gain from DPS' distribution strategy and innovation alongside Keurig's coffee brands and online presence. But, soft CSD trends and higher aluminum prices are woes.
Earnings Preview: Keurig Dr Pepper (KDP) Q3 Earnings Expected to Decline
by Zacks Equity Research
Keurig Dr Pepper (KDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coca-Cola (KO) Tops Q3 Earnings & Revenues, Retains View
by Zacks Equity Research
Solid growth strategies and productivity efforts aid Coca-Cola's (KO) earnings and sales in third-quarter 2018.
The Zacks Analyst Blog Highlights: PayPal, Schlumberger, Blackstone, V.F. and Keurig
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, Schlumberger, Blackstone, V.F. and Keurig
Top Stock Reports for PayPal, Schlumberger & Blackstone
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), Schlumberger (SLB) and Blackstone (BX).
Keurig Dr Pepper (KDP) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Keurig Dr Pepper (KDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molson Coors and HEXO Joint Venture Goes Live as "Truss"
by Zacks Equity Research
Molson Coors Canada (TAP) and Hydropothecary launch its JV, Truss, to explore the non-alcoholic cannabis-infused drinks market, just before cannabis trade is legalized in Canada.
PepsiCo (PEP) Q3 Earnings & Sales Top, Organic Sales View Up
by Zacks Equity Research
PepsiCo (PEP) delivers top and bottom line beat in third-quarter 2018 on strong performance in international division, alongside sequential revenue growth in NAB segment.
Keurig Dr Pepper (KDP) to Acquire CORE Nutrition for $525M
by Zacks Equity Research
Keurig Dr Pepper (KDP) signs an agreement to acquire CORE Nutrition LLC - a leading bottled water and other drinks' maker - for $525 million.
PepsiCo Holds Ground Despite Tough Conditions, Stock Gains 9%
by Zacks Equity Research
PepsiCO (PEP) rallies despite industry headwinds, including a shift to healthier drinks and higher costs. The company's snacking portfolio and innovation pipeline shows potential for further growth.
Keurig Dr Pepper (KDP) Down 3.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Keurig Dr Pepper (KDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Coke (KO) Stock a Buy After Costa Purchase & BodyArmor Investment?
by Benjamin Rains
Coca-Cola (KO) announced on Friday that it is set to purchase UK coffee giant Costa for $5.1 billion as it tries to expand its portfolio beyond sugary drinks. The move follows Coke's recent investment in sports drink upstart and potential Gatorade (PEP) rival BodyArmor. So, what should investors do with KO stock, which is down roughly 2% over the last 12 months, as the beverage behemoth readies itself for the future?
Coca Cola Agrees To Buy Costa Coffee
by Zacks Equity Research
Coca Cola Agrees To Buy Costa Coffee
Coke Buys U.K.'s Costa Coffee Ahead of Labor Day Weekend
by Mark Vickery
This price is a roughly 20% premium to the closing price of Costa's parent company, Whitbread, which trades on the London exchange.
Can Healthier Options Boost the U.S. Soft Drink Industry?
by Ritujay Ghosh
Following PepsiCo's announcement of acquiring SodaStream and Coca-Cola eying Moxie, it can be said that major soft beverage manufacturers are aggressively expanding their portfolio.